SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-15-002728
Filing Date
2015-08-14
Accepted
2015-08-14 16:02:24
Documents
10
Period of Report
2015-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vista10q_june302015.htm 10-Q 1476640
2 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-1.htm EX-31.1 9710
3 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER REQUIRED BY RULE 13A-14(A) UNDE ex31-2.htm EX-31.2 11246
4 CERTIFICATION OF THE PRINCIPAL EXECUTIVE AND FINANCIAL OFFICERS REQUIRED BY RULE ex32.htm EX-32 5901
  Complete submission text file 0001415889-15-002728.txt   4471289

Data Files

Seq Description Document Type Size
5 vsta-20150630.xml EX-101.INS 826546
6 vsta-20150630.xsd EX-101.SCH 49507
7 vsta-20150630_cal.xml EX-101.CAL 42231
8 vsta-20150630_def.xml EX-101.DEF 109931
9 vsta-20150630_lab.xml EX-101.LAB 243000
10 vsta-20150630_pre.xml EX-101.PRE 192775
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-244-9990
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 000-54014 | Film No.: 151055598
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences